Delivery Order SPE2DB22D2007-SPE2DB25FJ3LL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,132.00 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 4, 2025, with an ultimate completion date of August 5, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place...
- The Defense Logistics Agency awarded a delivery order valued at $22,621.69 to AmerisourceBergen Drug Corp for the supply of Xeljanz 10 mg tablets (60-count units) on August 5, 2025, with completion scheduled for August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $20,512.96 to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets (30-count units) under a firm fixed price contract. The award, issued on July 21, 2025, with an ultimate completion date of July 22, 2025, represents a non-competitive, competitively awarded delivery order with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xeljanz 5 mg tablets in quantities of 60 units, with a ceiling value of $6,416.32. This competitively awarded, firm fixed-price contract has an ultimate completion date of August 5, 2025, and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order does not include a set-aside designation and represents a child contract...
- The Defense Logistics Agency awarded a delivery order valued at $15,418.01 to AmerisourceBergen Drug Corp for the supply of XELJANZ XR 11 MG tablets in quantities of 30 units. This competitively awarded, firm fixed price delivery order is set to be completed by July 25, 2025, and represents a non-set-aside procurement. The award was issued on July 24, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Xeljanz XR 11 mg tablets (30-count units) valued at $8,107.66 under a firm fixed-price contract type. The award was made on July 22, 2025, with an ultimate completion date of July 23, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor providing critical medical supplies to federal healthcare...
- This delivery order, valued at $3,841.62, was awarded on July 30, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp for the supply of Xeljanz XR 11 mg tablets in quantities of 30 units. The contract represents a non-competitive set-aside delivery order with firm fixed pricing and a completion deadline of July 31, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is the place of performance and serves as the prime contractor on this order....
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Xeljanz XR 11 mg tablets (30-count units) with a ceiling value of $3,122.46 and an ultimate completion date of July 31, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with the Defense Logistics Agency. The contractor, headquartered in Conshohocken, Pennsylvania, serves...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Xeljanz XR 11 mg tablets in a quantity of 30-unit bottles. This is a firm fixed-price delivery order with a ceiling value of $12,834.49 and an ultimate completion date of August 5, 2025. The contract was competitively awarded with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which...
- The Defense Logistics Agency awarded a $2,477.39 delivery order to AmerisourceBergen Drug Corp for XELJANZ XR 11 MG tablets (30-count units) under a firm fixed price contract. This non-set-aside award, issued on August 1, 2025, with completion targeted for August 4, 2025, represents a routine pharmaceutical procurement supporting federal medical supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for the Defense...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ3LLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $25,569.98 to AmerisourceBergen Drug Corp for the supply of Xeljanz 5 mg tablets in quantities of 60 units. This firm fixed price delivery order, issued on July 30, 2025, is set to be completed by July 31, 2025, and represents a competitive award with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will fulfill this requirement from its corporate office location in the same city. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. This delivery order supports the Defense Logistics Agency's Medical Supply Chain mission to provide critical pharmaceutical products to military and federal healthcare systems. Xeljanz, a prescription immunosuppressant medication, represents the type of specialized therapeutic pharmaceutical that AmerisourceBergen routinely supplies through its DLA prime vendor relationship. The company's extensive federal procurement portfolio demonstrates consistent capability in delivering both brand-name and generic medications across multiple therapeutic domains to support military medical readiness and veteran healthcare requirements. This specific delivery order exemplifies the ongoing operational execution under AmerisourceBergen's master DLA contract for routine pharmaceutical procurement and distribution.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.6k | 7/30/25 |